Allison Frances O'Neill, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 11 | 2024 | 87 | 3.170 |
Why?
|
| Liver Neoplasms | 17 | 2024 | 4252 | 1.460 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2023 | 2214 | 1.440 |
Why?
|
| Li-Fraumeni Syndrome | 2 | 2017 | 114 | 0.720 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 222 | 0.720 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2020 | 450 | 0.570 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 546 | 0.520 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 484 | 0.480 |
Why?
|
| Copper Radioisotopes | 1 | 2013 | 86 | 0.450 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 664 | 0.440 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2016 | 526 | 0.420 |
Why?
|
| Vincristine | 5 | 2023 | 1036 | 0.400 |
Why?
|
| Cisplatin | 4 | 2023 | 1642 | 0.380 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 572 | 0.360 |
Why?
|
| Liver Transplantation | 3 | 2021 | 2118 | 0.350 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2016 | 3772 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11493 | 0.310 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 1602 | 0.300 |
Why?
|
| Child | 22 | 2023 | 77679 | 0.290 |
Why?
|
| Neoplasms | 4 | 2024 | 21672 | 0.270 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2525 | 0.270 |
Why?
|
| Calcium Channels | 4 | 2002 | 622 | 0.250 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 4841 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2002 | 871 | 0.230 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4837 | 0.230 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2662 | 0.230 |
Why?
|
| Calcium Signaling | 3 | 2002 | 721 | 0.230 |
Why?
|
| Fluorouracil | 2 | 2019 | 1616 | 0.230 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 2 | 2002 | 114 | 0.220 |
Why?
|
| Prognosis | 4 | 2022 | 29050 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9230 | 0.220 |
Why?
|
| Antigens, CD | 1 | 2013 | 4026 | 0.220 |
Why?
|
| Hepatectomy | 3 | 2022 | 550 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.210 |
Why?
|
| Glioblastoma | 1 | 2016 | 3481 | 0.190 |
Why?
|
| Sarcoma | 2 | 2023 | 1897 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 35423 | 0.180 |
Why?
|
| Pandemics | 1 | 2020 | 8387 | 0.180 |
Why?
|
| Vascular System Injuries | 1 | 2023 | 250 | 0.180 |
Why?
|
| Ludwig's Angina | 2 | 2009 | 6 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 6893 | 0.180 |
Why?
|
| Child, Preschool | 9 | 2021 | 40992 | 0.170 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2019 | 120 | 0.170 |
Why?
|
| Hepatocytes | 2 | 2002 | 1210 | 0.160 |
Why?
|
| Resource Allocation | 1 | 2020 | 341 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 13668 | 0.160 |
Why?
|
| Infant | 9 | 2022 | 35129 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 13096 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2023 | 729 | 0.150 |
Why?
|
| Fanconi Syndrome | 1 | 2017 | 35 | 0.150 |
Why?
|
| Humans | 39 | 2024 | 744220 | 0.150 |
Why?
|
| Adolescent | 12 | 2022 | 85759 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1061 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 280 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2020 | 694 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2024 | 53280 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 8860 | 0.130 |
Why?
|
| Doxorubicin | 2 | 2021 | 2220 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2019 | 1791 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 1057 | 0.120 |
Why?
|
| Camptothecin | 1 | 2017 | 576 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15294 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 720 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 8628 | 0.110 |
Why?
|
| Calcium | 3 | 2002 | 5757 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1831 | 0.100 |
Why?
|
| Antibody Specificity | 1 | 2013 | 1095 | 0.100 |
Why?
|
| Tissue Banks | 2 | 2024 | 184 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 1864 | 0.100 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2022 | 80 | 0.100 |
Why?
|
| Male | 17 | 2021 | 350027 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2017 | 1094 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 2886 | 0.090 |
Why?
|
| Ion Transport | 1 | 2011 | 320 | 0.090 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 4 | 2002 | 84 | 0.090 |
Why?
|
| Labial Frenum | 1 | 2009 | 6 | 0.090 |
Why?
|
| Carcinoma | 1 | 2021 | 2375 | 0.090 |
Why?
|
| Female | 15 | 2021 | 380197 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2011 | 218 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4929 | 0.090 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 1877 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2016 | 6274 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2013 | 2716 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2016 | 2017 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 11007 | 0.080 |
Why?
|
| Recurrence | 1 | 2019 | 8343 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2023 | 63119 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2948 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5529 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1123 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 3506 | 0.060 |
Why?
|
| Antibodies | 1 | 2013 | 2461 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2020 | 7730 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2020 | 3311 | 0.060 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 454 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2017 | 8321 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2021 | 11478 | 0.060 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 421 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2005 | 249 | 0.060 |
Why?
|
| Young Adult | 4 | 2023 | 56436 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 10250 | 0.060 |
Why?
|
| Thiosulfates | 1 | 2023 | 52 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2013 | 5974 | 0.050 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 2002 | 63 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2011 | 3769 | 0.050 |
Why?
|
| Photolysis | 1 | 2002 | 92 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3474 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2011 | 2454 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2005 | 359 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2002 | 284 | 0.050 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77426 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2009 | 2108 | 0.040 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2000 | 153 | 0.040 |
Why?
|
| Parenting | 1 | 2005 | 679 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2005 | 1317 | 0.040 |
Why?
|
| Adenosine Triphosphate | 2 | 2002 | 2025 | 0.040 |
Why?
|
| Leuprolide | 1 | 2020 | 311 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 1836 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 16687 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2005 | 1987 | 0.040 |
Why?
|
| Urban Population | 1 | 2005 | 2021 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1677 | 0.040 |
Why?
|
| Cytosol | 1 | 1999 | 901 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20123 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2005 | 2540 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2005 | 2053 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2021 | 25618 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 1814 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2019 | 542 | 0.030 |
Why?
|
| Microscopy, Confocal | 3 | 2011 | 1971 | 0.030 |
Why?
|
| Heparin | 1 | 2002 | 1637 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 18027 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 6485 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 40063 | 0.030 |
Why?
|
| Risk Factors | 4 | 2024 | 72280 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2009 | 7179 | 0.030 |
Why?
|
| Incidence | 2 | 2024 | 20945 | 0.030 |
Why?
|
| Disease Progression | 2 | 2021 | 13280 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3270 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 945 | 0.030 |
Why?
|
| Animals | 7 | 2019 | 168788 | 0.030 |
Why?
|
| Estrogens | 1 | 2020 | 1565 | 0.030 |
Why?
|
| Quinazolines | 1 | 2019 | 1356 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 3689 | 0.030 |
Why?
|
| Isomerism | 2 | 2002 | 201 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5076 | 0.030 |
Why?
|
| Rats | 3 | 2002 | 24273 | 0.020 |
Why?
|
| Parents | 1 | 2005 | 3407 | 0.020 |
Why?
|
| Cell Line | 2 | 2002 | 15999 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 6313 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 81178 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3557 | 0.020 |
Why?
|
| Methylamines | 1 | 2011 | 123 | 0.020 |
Why?
|
| Indoles | 1 | 2019 | 1838 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 2938 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10949 | 0.020 |
Why?
|
| Salivary Ducts | 1 | 2009 | 24 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1973 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1940 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 214035 | 0.020 |
Why?
|
| Clindamycin | 1 | 2009 | 139 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2021 | 23337 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 964 | 0.020 |
Why?
|
| Biopsy | 1 | 2020 | 6757 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2020 | 2940 | 0.020 |
Why?
|
| Zebrafish | 1 | 2019 | 2994 | 0.020 |
Why?
|
| Apoptosis | 2 | 2019 | 9728 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 10182 | 0.020 |
Why?
|
| Liver | 2 | 2000 | 7472 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2017 | 2616 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7281 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1420 | 0.020 |
Why?
|
| Prevalence | 1 | 2023 | 15226 | 0.020 |
Why?
|
| Gene Expression | 3 | 2005 | 7799 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 7908 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12781 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2005 | 67 | 0.020 |
Why?
|
| Base Sequence | 2 | 2011 | 12801 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 29784 | 0.020 |
Why?
|
| Philosophy | 1 | 2005 | 66 | 0.020 |
Why?
|
| Child Rearing | 1 | 2005 | 74 | 0.020 |
Why?
|
| Anthropology, Cultural | 1 | 2005 | 99 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2009 | 517 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 126 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 659 | 0.020 |
Why?
|
| Social Values | 1 | 2005 | 224 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 18116 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2005 | 347 | 0.010 |
Why?
|
| Acculturation | 1 | 2005 | 182 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3086 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5180 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 262 | 0.010 |
Why?
|
| Religion and Psychology | 1 | 2005 | 171 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2019 | 10480 | 0.010 |
Why?
|
| Extracellular Space | 1 | 2005 | 594 | 0.010 |
Why?
|
| New York City | 1 | 2005 | 710 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2005 | 579 | 0.010 |
Why?
|
| Cyclic ADP-Ribose | 1 | 2002 | 17 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2005 | 380 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 12961 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18367 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2563 | 0.010 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2002 | 176 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2002 | 206 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2005 | 1368 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2002 | 8302 | 0.010 |
Why?
|
| Child Welfare | 1 | 2005 | 523 | 0.010 |
Why?
|
| Vasopressins | 1 | 2002 | 370 | 0.010 |
Why?
|
| Hemostatics | 1 | 2002 | 229 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39045 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 2505 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3846 | 0.010 |
Why?
|
| Nucleotides | 1 | 2000 | 464 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4752 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 4567 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3611 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5892 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 3203 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 1801 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1999 | 23404 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 2133 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 1682 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 2839 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 5881 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 4321 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 2576 | 0.010 |
Why?
|
| Family | 1 | 2005 | 3148 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 16365 | 0.010 |
Why?
|
| Phylogeny | 1 | 2000 | 2803 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2000 | 1939 | 0.010 |
Why?
|
| United States | 1 | 2019 | 69867 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 3923 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2002 | 3690 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13036 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 19227 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 4803 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 13817 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 13885 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 11368 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 8950 | 0.000 |
Why?
|
| Middle Aged | 1 | 2017 | 213367 | 0.000 |
Why?
|